BioArctic Stock

BioArctic EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of BioArctic (BIOA B.ST) as of Aug 5, 2026 is 1.26 B SEK. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -222.14 M SEK — a change of -666.68% (higher).

EBITDA

1.26 BSEK

YoY

-666.68%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of BioArctic is 2026 1.26 B SEK. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of BioArctic was 2025 -222.14 M SEK. It decreases by -666.68% higher compared to the previous year.
Access this data via the Eulerpool API

BioArctic Stock analysis

What does BioArctic do? BioArctic AB is a Swedish biotechnology company founded in 2003. The company is based in Stockholm and focuses on the development of innovative therapeutics for nervous system diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. The company uses its expertise in biological and chemical drug research to discover and develop new therapeutic possibilities, with a focus on Amyloid-Beta production. BioArctic's business strategy is based on partnerships with pharmaceutical and biotech companies worldwide, working closely with partners to develop therapies and products that meet the needs and expectations of patients and doctors. BioArctic conducts research in three different areas: Alzheimer's, Parkinson's, and spinal cord injuries. The company works with partners such as Nutricia, Eisai, Just Biotherapeutics, Abcam, Neuropharm, AbbVie, Q-Med, Uppsala University, and the Karolinska Institute to develop treatments for these conditions. BioArctic has already brought several promising products to market, including BAN2401 for Alzheimer's and SC0806 for spinal cord injuries. Overall, BioArctic is a leading company in biological and chemical drug research, with a focus on developing new therapies and products for the benefit of patients and doctors worldwide. BioArctic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioArctic stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of BioArctic is 1.26 B SEK in 2026.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of BioArctic changed from -222.14 M SEK to 1.26 B SEK, representing a -666.68% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) BioArctic since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s BioArctic historically and in real time.

Access this data via the Eulerpool API

Income Statement — BioArctic

All Key Metrics — BioArctic